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ABSTRACT
Tumor necrosis factor (TNF) inhibitors account for a large proportion of drugs used to treat psoriasis and
are indicated first-line options in certain settings. Several biosimilar drugs based on the anti-TNF agents
adalimumab, infliximab, and etanercept are now available for use in patients with psoriasis. The favorable
cost differential of biosimilars is expected to improve access to biologic therapy for biologic-naive psoria-
sis patients, who are often undertreated. Also, substantial cost savings can be made if patients are
switched to biosimilars. To date, most clinical testing of anti-TNF biosimilars approved for use in psoriasis
has been performed in patients with rheumatoid arthritis, and the results extrapolated to psoriasis.
Although this may initially raise concerns for clinicians looking to start their psoriasis patients on biologic
treatment with a biosimilar or switch from an original biologic to a biosimilar, the process of extrapola-
tion is tightly regulated and scientifically justified. Furthermore, available real-world evidence of the safety
and efficacy of anti-TNF agents in patients with psoriasis complements clinical trial data in patients with
rheumatoid arthritis. When equipped with the appropriate knowledge, clinicians should have confidence
to use biosimilars for the treatment of psoriasis.
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Biologic therapies, such as monoclonal antibodies and receptor
fusion proteins targeting tumour necrosis factor (TNF) or interleu-
kins (ILs), such as IL-12/23 or IL-17, have greatly improved the
treatment options and outcomes for patients with moderate-to-
severe psoriasis [1,2,3]. Despite being significantly more effective
than conventional systemic agents for psoriasis, the high cost of
biologics may limit their use and contribute to inequalities of care
[1,4]. Data suggest that patients with moderate-to-severe psoriasis
who are currently receiving no systemic treatment or treatment
with conventional systemic agents, such as methotrexate or aci-
tretin, would benefit from biologic therapy [4]. Under-treatment
of psoriasis and accessibility to biologics are expected to improve
with the availability of lower cost biosimilar agents [1,3].
Unlike generic copies of small-molecule drugs that are widely
used as alternatives to more expensive originator products, the
complex molecular structure and cell culture manufacturing pro-
cess of biologics mean that they cannot be copied exactly [5].
The European Medicines Agency (EMA) states that a “biosimilar is
a biological medicinal product that contains a version of the
active substance of an already authorised biological medicinal
product (reference medicinal product) in the European Economic
Area (EAA) [6].” Biosimilar development is tightly regulated, with
the EMA stating that “similarity to the reference medicinal prod-
uct in terms of quality characteristics, biological activity, safety
and efficacy based on a comprehensive comparability exercise
needs to be established [6].” Likewise, the US Food and Drug
Administration (FDA) states that a biosimilar must be “highly sim-
ilar” to the reference product with “no clinically meaningful differ-
ences between the [biosimilar] product and the reference product
in terms of the safety, purity, and potency of the product [7].”
Overall, the development of a biosimilar product can be as exten-
sive as that of the reference product and is still associated with
significant costs, but compared with the development process for
reference products, there is more emphasis placed on physico-
chemical and functional characterisation of biosimilar drugs than
on clinical testing [5,8].
The anti-TNF agents adalimumab, etanercept and infliximab
were the first biologics to be approved in Europe for use in psor-
iasis [3]. Biosimilars based on these agents are now marketed for
use in psoriasis (Table 1), and many more are in development
[1,9]. To date, most clinical testing of anti-TNF biosimilars
approved for use in psoriasis has been performed in patients with
rheumatoid arthritis [9], who represent a patient population
sensitive enough to demonstrate even minor differences in
immunogenicity between the biosimilar and the reference prod-
uct [10]. This is an example of extrapolation, whereby biosimilars
are approved for use in indications of the reference product that
were not directly studied in clinical trials using the biosimilar [11].
Extrapolation reduces or eliminates the need for duplicative clin-
ical studies, thereby expediting the developmental process [11].
The EMA states that extrapolation must be “scientifically justified”
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and considered “in the light of the totality of the data, i.e. quality,
non-clinical and clinical data [6].” Clinical studies must be con-
ducted in a patient population sensitive enough for the detection
of differences in efficacy or safety between the biosimilar and the
reference product [6].
In this article, issues relevant to the rational and optimal inte-
gration of anti-TNF biosimilars into daily dermatology practice are
reviewed, including the role of anti-TNF biologic agents in the
treatment of psoriasis, quality attributes of anti-TNF biosimilars in
relation to their reference products, and real-world experience
with anti-TNF biosimilars in patients with psoriasis.
The biologic therapeutic landscape in psoriasis – role of
anti-TNF
Available biologics
In addition to three well-established anti-tumor necrosis factor
(TNF) agents (adalimumab, etanercept, and infliximab) and the
recently approved anti-TNF agent certolizumab pegol, biologic
agents approved in Europe for the treatment of psoriasis include
agents targeting IL-17 (brodalumab, ixekizumab, and secukinu-
mab), IL-23 (guselkumab), or IL-12/23 (ustekinumab) (1,12). Anti-
TNF agents have been available for the treatment of psoriasis for
more than 15 years and still account for a large proportion of
drugs used to treat psoriasis (51.1% share of 2017 market sales of
psoriasis drugs) (3,13). Biologic agents targeting IL-17 and IL-23
were introduced to the market relatively recently (3) and contrib-
ute to the substantial cost of treatment, with ustekinumab and
secukinumab accounting for 25.6% and 9.3% of 2017 market sales
of psoriasis drugs, respectively (13). Although biologic agents tar-
geting ILs have been shown to be very effective in the treatment
of psoriasis, long-term efficacy and safety data are relatively lim-
ited with these agents (4,14).
Treatment accessibility
Undertreatment is a significant problem in psoriasis, and the high
cost of biologic therapy is an important contributing factor (1,15).
In a 2011 National Psoriasis Foundation survey in the USA, up to
24% of patients with moderate-to-severe psoriasis were receiving
no therapy, and up to 30% of these patients were receiving top-
ical therapies alone (15), which in many cases may not be suffi-
cient. A retrospective study of patients treated with adalimumab,
etanercept, ustekinumab, or secukinumab for psoriasis in a
Spanish hospital from 2012 to 2016 reported a 30.7% increase in
patients receiving biologic treatment, mainly adalimumab and
ustekinumab, along with a 42% increase in costs over the time
period (16), reflecting the high costs of these drugs (17).
In the last few years, patent expiration and the resultant loss
of market exclusivity has facilitated the introduction of biosimilar
agents based on the anti-TNF biologic agents etanercept, inflixi-
mab and, most recently in October 2018, adalimumab, to clinical
care (18–20). Rheumatology data from Sweden, where switching
to biosimilars is not mandatory, show that when the etanercept
and infliximab reference products went off patent, there was an
increase in the overall use of biologic treatment, suggesting that
biosimilars were not only replacing the reference products, but
were increasing the overall rate of biologic therapy initiation (21).
This finding reflects the favorable cost differential of the anti-TNF
biosimilars (21). The recent introduction of adalimumab biosimi-
lars to the European market provides further opportunity to
improve cost savings and facilitate access to effective biologic
therapy (1,18,20). Compared with the current common practice of
no or delayed biologic therapy in patients with moderate-to-
severe psoriasis, earlier biologic intervention has the potential to
improve long-term patient outcomes (22).
Drug survival
Psoriasis is a chronic disease requiring effective long-term treat-
ment to manage the debilitating consequences, and societal and
economic burden of disease (23,24). However, drug survival data
from the DERMBIO registry, which contains data on all Danish
patients with moderate-to-severe psoriasis treated with biologics,
indicate that the investigated biologic drugs (adalimumab, etaner-
cept, infliximab, secukinumab, and ustekinumab) may eventually
all lose efficacy (Figure 1) (2). Anti-TNF agents (reference or biosi-
milar) may therefore be useful in patients experiencing loss of
response to biologic agents targeting ILs after long-term use, and
vice versa.
Anti-TNF from a comorbidity perspective
Psoriasis affects multiple systems in addition to the skin and is
therefore associated with an increased risk of various comorbid
diseases (23,25). Treatment should be personalized to address
comorbid conditions (25). Anti-TNF biologic agents are the recom-
mended first-line treatment of choice for several patient groups,
including those with comorbid psoriatic arthritis (PsA) or IBD (25).
In patients with comorbid PsA, which affects approximately 20%
of patients (26), ustekinumab may be used as an alternative to
anti-TNF agents if psoriasis is severe and arthritis is mild, and IL-
17 inhibitors should be considered in patients who do not
respond to TNF inhibitors (25). Ustekinumab may also be used in
Figure 1. The Kaplan–Meier plot of drug survival in patients with moderate-to-severe psoriasis from the DERMBIO registry treated with biologics (2).
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patients with Crohn’s disease, whereas secukinumab and ixekizu-
mab should be used cautiously or avoided, and brodalumab
should be avoided (25).
The evolving landscape of biosimilars – from quality
expectations to uninterrupted supply
Biopharmaceutical process modification and variability
of biologics
The structural complexity of biologic agents means that even
minor alterations in production processes and storage conditions
can affect product consistency and cause drifts in quality attrib-
utes (27). As a result of intentional changes in production proc-
esses, as well as the inevitable endogenous drift inherent to
biological systems, quality attributes of the reference products on
which biosimilars are based have changed over time and batch-
to-batch variability can occur (27–30). Different batches of refer-
ence biologic products can be found on the market at the same
time and can be used interchangeably (29).
Intentional biologic product manufacturing changes are tightly
regulated, and comparability exercises must be performed to
show that pre- and post-manufacturing change quality attributes
are sufficiently similar to indicate that there will be no impact on
clinical efficacy or safety (30,31). Nevertheless, compared with the
requirements for demonstrating biosimilarity, less sophisticated
methods and less comprehensive characterizations are required to
demonstrate batch-to-batch comparability of a biologic product
that has undergone a manufacturing change (32,33).
Demonstrating anti-TNF biosimilarity
Critical quality attributes (CQAs) of biosimilars are selected based
on criticality ranking of quality attributes in relation to their
potential impact on immunogenicity, safety, pharmacokinetics,
and efficacy (34). For example, the neutralization effect of TNF
binding is a CQA of anti-TNF biosimilars (33,35). To ensure that
there are no clinically relevant differences between the biosimilar
and the reference product, and reduce the need for clinical test-
ing, CQAs must be within similarity ranges that account for batch-
to-batch variability of the reference product in recent years
(29,32). For example, the results of TNF neutralization assays,
which reflect the potency of anti-TNF biosimilar products, should
be within the similarity range defined for the anti-TNF reference
product, as demonstrated during comparability exercises involving
etanercept biosimilar SB4 in relation to multiple batches of EU-
and US-sourced product (Figure 2) (35). It is also very important
to assess CQAs that can affect the pharmacokinetic profile of anti-
TNF biosimilars, such as neonatal Fc receptor binding in the case
of monoclonal antibodies, and ensure they are within the similar-
ity range of the reference product (33,36).
Although the characterization of biosimilars in relation to CQAs
affecting efficacy and pharmacokinetics is very important, the pri-
mary concern with biosimilars is a theoretical risk of immunogen-
icity, whereby anti-drug antibodies and neutralizing antibodies
can adversely affect pharmacokinetics, safety, and efficacy (29,37).
However, full characterization of biosimilars using state-of-the-art
technology reduces this risk. For example, aggregation of biologic
proteins increases the risk of immunogenicity, and levels of aggre-
gate can now be determined by analytical methods, so similar or
lower levels of aggregate in the biosimilar compared with the ref-
erence product should be demonstrated (29,32). Moreover, in con-
trast to the last 10–15 years, assays are now available that
sensitively characterize antidrug antibodies and neutralizing anti-
bodies in serum samples. Thus, the clinical immunogenicity of
biosimilars can be assessed relatively reliably (38). For example,
results from a study comparing specific antigenic epitopes
between CT-P13 and infliximab reference product have recently
been reported, and suggest the two drugs have similar epitope
binding profiles and equivalent immunogenicity (39).
Although the overall structural, physicochemical and biological
quality attributes of the etanercept biosimilar SB4 were shown to
be highly similar to the reference product during extensive com-
parability exercises using state-of-the-art methods, SB4 was found
to contain lower levels of potentially immunogenic high molecu-
lar weight aggregate (i.e. not within the similarity range of the
reference product) (35). It was hypothesized that this could be
beneficial in terms of safety and immunogenicity (35). In line with
this hypothesis, equivalent efficacy was demonstrated for SB4 and
etanercept reference product in relation to the American College
of Rheumatology (ACR) 20 response at 24 weeks in a phase III trial
of patients with rheumatoid arthritis, but SB4 was associated with
significantly fewer injection-site reactions up to week 52, and less
immunogenicity than the reference product (40,41). These find-
ings emphasize the importance of publishing biosimilar quality
data to better understand biosimilar clinical trial data.
Importance of supply
In the event of a drug shortage, whereby the company cannot
supply the market with recently produced drugs, drug batches
with different expiry dates and potentially different quality profiles
and activities will be on the market. The importance of pharmaco-
vigilance at batch level, and the importance of batch traceability
are reflected in the EMA assessment of the infliximab biosimilar
Figure 2. Comparison of TNF neutralization activity of SB4 and etanercept reference product (40 lots of EU-sourced product and 40 lots of US-sourced product), with
the dotted line indicating the similarity range based on results of etanercept reference product obtained from the EU (35).
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CT-P13, in which it was reported that the protein content of the
reference product fell below the proposed CT-P13 end-of-shelf-life
specification during 12 months of stability testing (42). This was
attributed to the fact that the reference product batches were
older than the CT-P13 batches when the study was initiated (42).
Rigorous post-marketing pharmacovigilance using biosimilar regis-
tries is important to monitor the long-term efficacy and safety of
anti-TNF biosimilars. In relation to this, prescribers and pharma-
cists should ensure adequate registration of the biosimilar brand
name, batch number, and expiration date.
Biosimilars in daily practice – real-world evidence
With its favorable and well-established safety profile, reliable effi-
cacy and flexibility of dosing, etanercept, which was one of the
first biologic drugs approved for use in psoriasis, is still a very
important treatment option for patients with psoriasis (43). SB4
was the first biosimilar of etanercept to be authorized for market-
ing in the EU (35). Real-world data demonstrating the effective-
ness and safety of SB4 in patients with psoriasis are now
emerging from various national registries to complement clinical
trial data in patients with rheumatoid arthritis (2,44,45). Real-world
evidence for the safety and effectiveness of SB4 in patients with
psoriasis is, however, currently limited to short-term data
(6 months) (44,45). Longer-term safety and efficacy monitoring of
large populations is necessary and ongoing (44,45). Limited real-
world data are also available for the infliximab biosimilar CT-P13
in patients with psoriasis (2,46,47). Adalimumab biosimilars have
only very recently entered the European market (20), so there is
no substantial real-world data with any of these drugs.
National registry data
The PsoBiosimilars Registry is an Italian registry of anti-TNF biosi-
milars in psoriasis and PsA (45,47). As of July 2018, 39 centers had
registered a total of 197 patients treated with SB4 (158 patients
switched from reference etanercept and 39 etanercept-naive
patients). Over 6 months of treatment, the Psoriasis Area and
Severity Index (PASI) score was significantly reduced in the etaner-
cept-naive patients, and efficacy was maintained in patients
switched from reference etanercept to SB4 (Figure 3) (45). A PASI
75 response occurred in 20 (51%) etanercept-naive patients. There
was no significant difference in the number of adverse events
between switch patients and etanercept-naive patients. Similar
observations from the PsoBiosimilars Registry have been reported
for the infliximab biosimilar CT-P13 (47).
PASI data from the British BADBIR registry also indicate that
SB4 is an effective treatment option in patients with psoriasis (44).
Of 92 patients who started SB4 in the first half of 2017 for a
mean treatment period of 322.3 ± 127.1 days (five patients were
switched from reference etanercept), nine patients (9.8%) discon-
tinued treatment (mean treatment time to discontinuation of
137 ± 71.9 days). This was due to lack of effectiveness (n¼ 6),
adverse events (n¼ 2) or a combination of these problems (n¼ 1).
None of the five patients who switched from reference etanercept
to SB4 discontinued treatment during the observation period.
Analysis of data from the Danish DERMBIO registry showed
that switching patients with moderate-to-severe psoriasis from
reference etanercept to SB4 had no significant impact on drug
survival (Figure 4) (2). The hazard ratio (HR) for risk of discontinu-
ation of SB4 versus reference etanercept was 0.46 (p¼.297). There
was also no significant difference in the risk of discontinuation of
CT-P13 versus reference infliximab (HR 1.64; p¼.264). In these
analyses, a total of 147, 114, 44, and 34 treatment series were
included for etanercept, infliximab, SB4, and CT-P13, respectively.
Clinical trial switching data
A recent systematic review of more than 90 studies, including
randomized clinical trials and observational studies providing real-
world evidence, in 14,225 patients in 14 disease indications,
including psoriasis, suggested that patients can be switched from
a reference biologic to a biosimilar in any indication without con-
cerns for safety or loss of efficacy (48). The greatest amount of
clinical trial switching data for adalimumab, etanercept, and inflixi-
mab biosimilars are in patients with rheumatoid arthritis (49–53),
but studies have also been conducted with adalimumab and eta-
nercept biosimilars in patients with psoriasis (54–56). Patients
with psoriasis were also included in the NOR-SWITCH study,
assessing a switch from reference infliximab to CT-P13 versus con-
tinued treatment with reference infliximab, but the study was not
powered to demonstrate noninferiority of the switch for separate
indications (57). Collectively, all of these studies, including those
conducted in other indications, supported a switch from reference
product to biosimilar in patients with psoriasis (Table 1).
Although there may be concerns that the majority of pivotal
trials with anti-TNF biosimilars have not been conducted in
patients with psoriasis (1,9), the European biosimilar development
and approval process, based on the totality of the evidence and
appropriate scientific justification (6), means that if an anti-TNF
biosimilar drug is shown to be effective in rheumatoid arthritis it
is also likely to be effective in psoriasis. National registry data for
the etanercept biosimilar SB4 and the infliximab biosimilar CT-P13
Figure 3. Psoriasis Area and Severity Index (PASI) scores during 6 months of treatment with etanercept biosimilar SB4 in patients from the PsoBiosimilars registry
switched from reference etanercept and in etanercept-naive patients (45). p<.05 vs. baseline.
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support this assertion (44,45,47). Although there are currently no
real-world data for adalimumab biosimilars in patients with psor-
iasis, robust, randomized, double-blind, switching evidence for
these drugs comes from phase III studies of ABP 501 and GP2017
in patients with psoriasis (54,56), and BI 695501 and SB5 in
patients with rheumatoid arthritis (49,53).
Conclusions
Anti-TNF biosimilars approved by regulatory authorities can be a
safe and effective treatment option for patients with psoriasis. In
the face of ever-increasing healthcare costs and cost-cutting initia-
tives, switching patients from reference adalimumab, etanercept,
or infliximab to a lower cost biosimilar, and starting biologic-naive
patients on the best-value biologic can lower prices for patients
and payers without compromising quality of care. Cost savings
from use of anti-TNF biosimilars provide an opportunity for physi-
cians to prescribe effective biologic therapy for more patients
with moderate-to-severe psoriasis who could benefit from it.
However, to realize the cost-saving potential of biosimilars in
patients with psoriasis, clinicians must have the confidence to use
them. Educating clinicians about the scientific principles underly-
ing biosimilar development and approval, and real-world clinical
experience with these drugs in patients with psoriasis may help
them to make informed treatment decisions and lead to wider
use of biologics in clinical practice (1).
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Figure 4. The Kaplan–Meier plot of drug survival in patients with moderate-to-severe psoriasis in the DERMBIO registry treated with reference etanercept or switched
from reference etanercept to etanercept biosimilar SB4 (2).




Code name Brand name Drug company
Clinical studies conducted
for approval Approval year
Infliximab (Remicade) CT-P13 Inflectra/Remsima Celltrion AS, RA 2013
SB2 Flixabi Samsung Bioepis RA 2016
PF-06438179/GP111 Zessly Sanodoz RA 2018
Etanercept (Enbrel) SB4 Benepali Samsung Bioepis RA 2016
GP2015 Erelzi Sandoz PsO 2017
Adalimumab (Humira) ABP501 Amgevita/Solymbic Amgen PSO, RA 2017
SB5 Imraldi Samsung Bioepis RA 2017
BI 695501 Cyltezo Boehringer Ingelheim RA 2017
GP2017 Halimatoz/Hefiya/Hyrimoz Sandoz PsO 2018
FKB327 Hulio Fujifilm Kyowa Kirin Biologics RA 2018
AS: ankylosing spondylitis; EMA: European Medicines Agency; INN: International Nonproprietary Name; PsO: psoriasis; RA: rheumatoid arthritis.
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